ZSP1601

DRUG2 trials

Sponsors

Guangdong Raynovent Biotech Co., Ltd

Conditions

Non-Alcoholic Steatohepatitis (NASH)Nonalcoholic Steatohepatitis (NASH)

Phase 1

Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)

CompletedNCT04140123

Guangdong Raynovent Biotech Co., LtdNon-Alcoholic Steatohepatitis (NASH)

Start: 2020-06-23End: 2021-08-03Updated: 2021-10-11

Phase 2

A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

Active, not recruitingNCT05692492

Guangdong Raynovent Biotech Co., LtdNonalcoholic Steatohepatitis (NASH)

Start: 2023-06-03End: 2026-12-16Updated: 2025-03-19

Related Papers

ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial.

2023-10-1213 citations